Greater Boston
With over 20 years of experience as a physician-scientist, I am passionate about advancing the understanding and treatment of human diseases with unmet medical needs. I currently lead the research and development function at Carmot Therapeutics, Inc., a biotechnology company that leverages a novel drug discovery platform to create innovative therapies for metabolic conditions such as diabetes, obesity, and liver diseases. I have a proven track record of delivering results across the drug development continuum, from discovery to registration, with expertise in cellular signaling, translational medicine, clinical pharmacology, biomarker development, clinical development, and regulatory affairs. I have successfully managed multiple global clinical trials, led cross-functional teams, and established strategic partnerships with external stakeholders. I also have a strong academic background, with an MD and a PhD in cell biology and physiology, and a clinical assistant professorship at Rutgers New Jersey Medical School. I enjoy teaching and mentoring the next generation of scientists and clinicians, and I am always eager to learn from others and share my insights. My mission is to bring my creativity, vision, and collaboration skills to make a positive impact on patients' lives and health outcomes.
Teaching Medical Students, Residents, and Endocrine Fellows; attend on the out-patient Lipid Clinic
Direct oversight of all phases of clinical development across several indications, regulatory affairs, quality, and scientific communications, and responsible for the strategic direction and oversight for Axcella’s clinical research and development activities.
Direct oversight of all phases of clinical development across several indications, regulatory affairs, quality, and scientific communications, and responsible for the strategic direction and oversight for Axcella’s clinical research and development activities.
Responsible for external search and evaluate activities and R&D strategy in support of diabetes (+ complications) and cardio-renal efforts to shape and implement external innovation for Lilly.